Compare Quest Diagnostics Inc (DGX) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Opendoor Technologies Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Opendoor Technologies Inc trades at $2.31 (market cap $2.20B). The key difference: Quest Diagnostics Inc is far larger — about 11.4× Opendoor Technologies Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Opendoor Technologies Inc for 33 Days on average.
| DGX | OPEN | |
|---|---|---|
Market Cap | $25.06B | $2.20B |
Volume | 927,361 | 35,582,488 |
Sector | Health | Real Estate |
52-Week High | $247.45 | $9.37 |
52-Week Low | $173.49 | $2.27 |
Typical Hold Time | 56 Days | 33 Days |
Enterprise Value | $30.82B | $3.27B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Opendoor Technologies trades at $2.29, up 0.88% with a bearish technical outlook. The company shows concerning fundamentals with a -46.74% net income margin and -$1.3B net loss despite $4.37B revenue. Recent earnings misses and negative cash flow trends highlight operational challenges, though mortgage expansion to 35-40 states by end-2026 offers potential growth. Analyst consensus is mixed with 26.9% buy ratings but a $4.92 price target suggesting 115% upside from current levels.
The stock presents high-risk speculative potential with significant operational turnaround required. While valuation appears attractive at 0.62 P/S ratio, persistent losses and housing market sensitivity create substantial downside risk. The mortgage expansion initiative could drive recovery if execution improves, but investors face volatility from rate sensitivity and competitive pressures in the iBuyer space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
